Danoprevir

Star0

DB11779InvestigationalSmall molecule

Danoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.

Mechanism: Danoprevir is a NS3/4A protease inhibitor. The HCV NS3/4A protease is an attractive drug target because of its potential involvement in viral replication and suppressive effects on host response to viral infection. Inhibitors of the HCV protease, such as Danoprevir, represent a promising new class of drugs for HCV.
Curator reviewed
Formula / weight: C₃₅H₄₆FN₅O₉S · 731.84 g/mol (avg)
Code names: R-05190591 · RO-5190591

Resolves to

Compound

UNII911Z9PCQ5FCAS850876-88-9ChEMBLCHEMBL258734PubChem11285588

Structure

InChIKeyZVTDLPBHTSMEJZ-JSZLBQEHSA-NSMILESCC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1CC2=CC=CC(F)=C2C1)C(=O)NS(=O)(=O)C1CC1

Targets

P03366gag-polP26664Genome polyprotein

What you can answer from here — as of September 13, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

807Drug interactionsStructured to mechanism, not free text

11Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Danoprevir, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account